Natale v. Pfizer, Inc.

379 F. Supp. 2d 161, 2005 U.S. Dist. LEXIS 15350, 2005 WL 1793451
CourtDistrict Court, D. Massachusetts
DecidedJuly 28, 2005
DocketCIV.A.05-10590-WGY, CIV.A.05-10591-WGY
StatusPublished
Cited by19 cases

This text of 379 F. Supp. 2d 161 (Natale v. Pfizer, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Natale v. Pfizer, Inc., 379 F. Supp. 2d 161, 2005 U.S. Dist. LEXIS 15350, 2005 WL 1793451 (D. Mass. 2005).

Opinion

MEMORANDUM AND CERTIFICATION

YOUNG, Chief Judge.

Jerry Natale, on behalf of himself and all others similarly situated (“Natale”), and Sherry Kwaak, on behalf of herself and all others similarly situated (“Kwaak”), challenge the removal of this case from state court and whether this Court, pursuant to the Class Action Fairness Act of 2005, Pub.L. No. 109-2 (2005) (the “Act”) (amending 28 U.S.C. §§ 1332, 1453), properly has jurisdiction over these matters. *163 The motions to remand of Natale, Civ. Action No. 05-10590, and Kwaak, Civil Action No. 05-10591, will be treated identically here for discussion purposes. 1

Section 9 of the Act provides that the Act applies to any case “commenced on or after [February 18, 2005,] the date of enactment,” of the new federal class action law. Pub.L. No. 109-2 (emphasis added). The controlling issue to be decided by this Court is: under section 9 of the Class Action Fairness Act of 2005, is a civil action “commenced” on the date a class action complaint is filed by a plaintiff in the state court or on the date a case is removed by a defendant to the federal court? This Court answers this question as did the United States Courts of Appeals for the Seventh and Tenth Circuits and holds that an action is commenced as of the date of filing in the state court.

I. Relevant Facts and Procedural History

A. Natale v. Pfizer

On February 14, 2005, Natale commenced this action by filing his state court class action complaint in the Massachusetts Superior Court sitting in and for the County of Middlesex (“Middlesex Superior Court”). Mem. in Supp. of Mot. to Remand [Civ. A. No. 05-10590 Doc. No. 10] at 3 (“Natale Mem.”). Natale sought “certification of a statewide class consisting of all Massachusetts consumers who purchased Listerine® Antiseptic Mouthrinse [] between February 11, 2002 and the present.” Id. The advertising statement that was the subject of the class action suit was: “Listerine as effective as Floss — Clinical studies prove it.” Id. Na-tale argues that this statement “knowingly contained materially false and misleading misrepresentations, statements and omissions” and seeks to receive damages under a theory of common law fraud. Id.

On March 25, 2005, Pfizer filed, pursuant to the Act, a notice of removal with the United States District Court removing the civil action from the Middlesex Superior Court. Id. at 4. Pfizer asserts that federal diversity jurisdiction exists under the new Act and argues that, under section 9 of the Act, a case is commenced in federal court upon a timely removal to federal court rather than on the date of filing with the state court.

B. Kwaak v. Pfizer

Kwaak filed her state class action complaint against Pfizer in the Middlesex Superior Court on January 13, 2005, and a first amended complaint on March 2, 2005. Mem. of Law in Supp. of Pl.’s Mot. to Remand [Civ. A. No. 05-10591 Doc. No. 11] at 3 (“Kwaak Mem.”). Like Natale, Kwaak seeks “certification of a statewide class consisting of all Massachusetts consumers who purchased Listerine® Antiseptic Mouthrinse [] from June 1, 2004 through the present.” Id. The Kwaak case focuses on the same allegedly misleading misrepresentation — “Listerine ® as effective as Floss — Clinical studies prove it” — as does Natale’s claim. Id. Kwaak seeks damages for herself and the class under the theory of unjust enrichment and under the Massachusetts consumer protection act. Id.; Mass. Gen. Laws ch. 93A, § 2.

On March 25, 2005, Pfizer filed a notice of removal with the district court again arguing that federal diversity jurisdiction exists pursuant to the removal provisions of the Act because “commence” means removal to the federal court. Kwaak Mem. *164 at 4. In Kwaak’s matter, Pfizer argues in the alternative that federal diversity jurisdiction exists because Kwaak’s “request for relief in the form of disgorgement among all class members is a ‘common and undivided interest’ in excess of $75,000, exclusive of interest and costs.” Id.

The parties presented oral argument on June 13, 2005 as to whether this Court has jurisdiction over this matter pursuant to the Class Action Fairness Act of 2005. This Court took the matter under advisement properly to consider and interpret the Act as applied to these matters. Tr. of Mot. Hr’g of June 13, 2005 at 13.

II. Class Action Fairness Act of 2005

A. General Overview of the Act

The Class Action Fairness Act of 2005 was passed by Congress and signed into law by President George W. Bush on February 18, 2005. 2 Pub.L. 109-2 (2005). Its enactment was heralded as a product of bipartisan efforts. 3 Yet, the Act was the subject of much controversy and debate. 4 *165 See 151 Cong. Rec. H643-01, H643 (daily ed. Feb. 16, 2005) (statement of Rep. Gingrey) (noting that “[e]ven with such bipartisan support ... there are differences of opinion on how to reform our class action system.”); Rick Knight, The Class Action Fairness Act of 2005: A Perspective, 52 Fed. Law. 46 (June 2005) (“[D]espite the roiling public brouhaha surrounding this and other — so-called national litigation — reform, the jury is likely to be out on [the Act] ... for years to come.”).

The Act is expected by1 some to be “problematic.” Georgene M. Vairo, Class Action Fairness, Nat’l L.J., June 27, 2005 at 12. It was enacted to “address some of the most egregious problems in class action practice.” The Class Action Fairness Act of 2005, Dates of Consideration and *166 Passage, S. Rep. 109-14, 2005 U.S.C.C.A.N. 3, 6 (describing the legislation as a “modest, balanced step” and not a “panacea” in reform). Among other things, the Act amends 28 U.S.C. § 1332, in pertinent part, to establish original subject matter jurisdiction in federal courts 5 over class actions, and amends 28 U.S.C. § 1453, to allow removal jurisdiction from state courts 6 in those cases in which (1) *167 the class consists of at least 100 proposed members; (2) the matter in controversy is greater than $5,000,000 after aggregating the claims of the proposed class members, exclusive of interest and costs, Pub.L.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bailey v. United States (In re Bailey)
592 B.R. 400 (First Circuit, 2018)
Haber v. Massey
904 F. Supp. 2d 136 (D. Massachusetts, 2012)
McMorris v. TJX Companies, Inc.
493 F. Supp. 2d 158 (D. Massachusetts, 2007)
Katie Lowery v. Honeywell International, Inc.
483 F.3d 1184 (Eleventh Circuit, 2007)
Everett v. Verizon Wireless
Sixth Circuit, 2006
Moniz v. Bayer A.G.
447 F. Supp. 2d 31 (D. Massachusetts, 2006)
Frazier v. Pioneer Americas LLC
455 F.3d 542 (Fifth Circuit, 2006)
Eufaula Drugs, Inc. v. Tmesys, Inc.
432 F. Supp. 2d 1240 (M.D. Alabama, 2006)
Steinberg v. Nationwide Mutual Insurance
418 F. Supp. 2d 215 (E.D. New York, 2006)
Werner v. KPMG LLP
415 F. Supp. 2d 688 (S.D. Texas, 2006)
Rodgers v. Central Locating Service, Ltd.
412 F. Supp. 2d 1171 (W.D. Washington, 2006)
Delaventura v. Columbia Acorn Trust
417 F. Supp. 2d 147 (D. Massachusetts, 2006)
Ongstad Ex Rel. Ongstad Family Trust v. Piper Jaffray & Co.
407 F. Supp. 2d 1085 (D. North Dakota, 2006)
Bush v. Cheaptickets, Inc.
425 F.3d 683 (Ninth Circuit, 2005)
In re Relafen Antitrust Litigation
231 F.R.D. 52 (D. Massachusetts, 2005)

Cite This Page — Counsel Stack

Bluebook (online)
379 F. Supp. 2d 161, 2005 U.S. Dist. LEXIS 15350, 2005 WL 1793451, Counsel Stack Legal Research, https://law.counselstack.com/opinion/natale-v-pfizer-inc-mad-2005.